Grifulvin V exerts its therapeutic effect through a unique fungistatic mechanism. It specifically inhibits fungal mitosis by disrupting the mitotic spindle. The drug binds to microtubular proteins, particularly tubulin, which are essential for the formation of the spindle apparatus during cell division. This disruption prevents the proper segregation of chromosomes, halting the fungal cells in metaphase. Crucially, griseofulvin is selectively concentrated in keratin precursor cells. As these cells differentiate and form the keratin of skin, hair, and nails, the drug is incorporated into these tissues, creating an environment hostile to fungal invasion. New, healthy keratin replaces the infected keratin, effectively “growing out” the infection. This mechanism makes it specifically effective against fungi that infect keratinized tissues.<\/p>\n<\/p>\n
![](\"https:\/\/burst.shopifycdn.com\/photos\/church-organ-in-alcove.jpg?width=746&format=pjpg&exif=0&iptc=0\")
<\/p>\n
Indications and Clinical Use<\/strong><\/p>\n Grifulvin V is indicated for the treatment of dermatophytoses (ringworm infections) that are severe, extensive, or resistant to topical antifungal therapy. Its primary uses include:<\/p>\n Tinea capitis:<\/strong> Fungal infection of the scalp and hair, which is its most common and important indication, especially in children.<\/p>\n <\/em> Tinea unguium (onychomycosis):<\/strong> Infection of the fingernails or toenails, though it requires prolonged therapy and has lower cure rates compared to newer agents like terbinafine.<\/p>\n Tinea corporis:<\/strong> Extensive ringworm of the body.<\/p>\n <\/em> Tinea pedis:<\/strong> Severe athlete’s foot.<\/p>\n Tinea barbae:<\/strong> Fungal infection of the beard area.<\/p>\n It is not effective against candidiasis (yeast infections), bacterial infections, or systemic fungal infections like histoplasmosis.<\/p>\n<\/p>\n Pharmacokinetics<\/strong><\/p>\n Griseofulvin is administered orally in microsize (Grifulvin V) or ultramicrosize formulations, with the latter having better absorption. Absorption is variable and significantly enhanced by a fatty meal. The drug is metabolized extensively in the liver by the cytochrome P450 system, primarily by the CYP3A4 enzyme. Its half-life is approximately 9-24 hours, necessitating once or twice-daily dosing. Less than 1% of the unchanged drug is excreted in urine; the majority is eliminated in feces via bile.<\/p>\n<\/p>\n Dosage and Administration<\/strong><\/p>\n Dosage is weight-based, especially for children. For adults, typical microsize (Grifulvin V) dosage ranges from 500 mg to 1 gram daily, usually in divided doses. Treatment duration is prolonged and depends on the site of infection:<\/p>\n <\/em> Tinea capitis: 4 to 6 weeks.<\/p>\n Tinea unguium: Fingernails require a minimum of 4 months; toenails require a minimum of 6 months, often longer.<\/p>\n Therapy must continue until the infected keratin is completely replaced, which requires clinical and laboratory confirmation of cure. Compliance with the lengthy regimen is a significant challenge.<\/p>\n<\/p>\n Adverse Effects<\/a> and Tolerability<\/strong><\/p>\n Grifulvin V is generally well-tolerated but is associated with a range of potential side effects.<\/p>\n <\/em> Common:<\/strong> Headache (often initial and transient), gastrointestinal upset, and cutaneous reactions like rash or urticaria.<\/p>\n Hepatobiliary:<\/strong> Rare instances of hepatotoxicity, including hepatitis and cholestatic jaundice, necessitate periodic liver function monitoring.<\/p>\n <\/em> Neurological:<\/strong> Dizziness, insomnia, confusion, and peripheral neuropathy have been reported.<\/p>\n Hematological:<\/strong> Rare but serious leukopenia and granulocytopenia.<\/p>\n <\/em> Hypersensitivity:<\/strong> Reactions ranging from skin rashes to severe syndromes like Stevens-Johnson syndrome.<\/p>\n Other:<\/strong> Photosensitivity, proteinuria, and oral thrush due to alteration of gut flora.<\/p>\n<\/p>\n Drug Interactions<\/strong><\/p>\n Griseofulvin is a potent inducer of hepatic cytochrome P450 enzymes. This leads to significant interactions:<\/p>\n <\/em> It decreases the efficacy of warfarin<\/strong> (anticoagulant), requiring increased warfarin dosage and careful INR monitoring.<\/p>\n It reduces plasma levels of oral contraceptives<\/strong>, potentially leading to contraceptive failure and breakthrough bleeding. Alternative or backup contraceptive methods are advised.<\/p>\n <\/em> It may diminish the effects of cyclosporine<\/strong>, theophylline<\/strong>, and certain barbiturates.<\/p>\n Concurrent use with alcohol<\/strong> can cause disulfiram-like reactions (flushing, tachycardia).<\/p>\n <\/em> Its absorption is reduced by phenobarbital<\/strong>.<\/p>\n<\/p>\n Contraindications and Precautions<\/strong><\/p>\n Grifulvin V is contraindicated in patients with porphyria (it can precipitate acute attacks), hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin. It is Pregnancy Category C (older classification) and should be avoided in pregnancy, especially in the first trimester, due to potential teratogenic and embryotoxic effects. It is excreted in breast milk and is not recommended for nursing mothers. Caution is required in patients with pre-existing liver disease or systemic lupus erythematosus.<\/p>\n<\/p>\n